| Company: | INSYS Therapeutics, Inc |
| Ticker Symbol: | INSY |
| Class Period: | May-2-13 to May-8-14 |
| Date Filed: | May-26-14 |
| Lead Plaintiff Deadline: | Jul-25-14 |
| Court: | District of Arizona |
| Allegations: | |
INSYS is a specialty pharmaceutical company that develops and commercializes innovative supportive care products. The Company has two marketed products -- a generic equivalent to Marinol for chemotherapy-induced nausea, vomiting and anorexia in patients with AIDS, and Subsys, a proprietary sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant patients.
The Complaint alleges that throughout the Class Period defendants issued false and/or misleading statements and/or failed to disclose: (1) the Company's illegal and/or improper marketing of Subsys; (2) that improper marketing of Subsys could lead to regulatory scrutiny; (3) that such regulatory scrutiny could expose the Company to potential fines and other disciplinary actions; and (4) as a result of the foregoing, that the Company's financial statements were materially false and misleading at all relevant times.
If you acquired the securities of the defendants during the Class Period you may, no later than the Lead Plaintiff Deadline shown above, request that the Court appoint you as lead plaintiff through counsel of your choice. You may also choose to remain an absent class member. A lead plaintiff must meet certain requirements.
